Micardis HCT and Mycophenolate Mofetil Oral Suspension

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Telmisartan may decrease the blood levels and effects of mycophenolate mofetil. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your symptoms worsen or your condition changes during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with telmisartan may decrease the plasma concentrations and therapeutic effects of mycophenolate mofetil (MMF). Concomitant use of telmisartan with MMF resulted in an approximately 30% decrease in mycophenolic acid (MPA) concentrations. The proposed mechanism is increased clearance due to telmisartan-mediated induction of UGT1A9. Adverse effects, such as graft rejection in transplant patients, have not been reported.

MANAGEMENT: Until more information is available, caution is advised when telmisartan is used concomitantly with mycophenolate mofetil. Dosage adjustments as well as clinical and laboratory monitoring should be considered.

Micardis HCT

Generic Name: hydrochlorothiazide / telmisartan

Brand name: Micardis HCT

Synonyms: n.a.

What is Micardis HCT?

Mycophenolate Mofetil Oral Suspension

Generic Name: mycophenolate mofetil

Brand name: Cellcept, Myfortic, MMF

Synonyms: Mycophenolate mofetil (oral/injection), Mycophenolate

What is Mycophenolate Mofetil Oral Suspension?